Media room archive

The HARTMANN GROUP expects moderate organic sales growth and adjusted EBITDA in the range of EUR 200 to 240 million for the 2024 financial year. This represents an increase compared to the last earnings forecast for 2023 of EUR 180 to 210 million.

Oliver Neubrand will be the new CFO of the HARTMANN GROUP. He will resume responsibility on January 1, 2024, and will be responsible for Controlling, Finance, Accounting, Mergers & Acquisition, Risk Management, Legal, IT, Investor Relations and the businesses CMC and IVF HARTMANN in Switzerland.

From January to September 2023, the HARTMANN GROUP generated sales revenues of EUR 1,747.2 million. This corresponds to organic sales growth of 2.5% compared to the same period of the previous year.

PAUL HARTMANN AG has been nominated for the German Sustainability Award in the field of medical technology. Honoring companies for their sustainability achievements, the award is being given this year for the 16th time by the German Sustainability Award Foundation in cooperation with the German government.

In the first six months of financial year 2023, the HARTMANN GROUP generated sales revenues of EUR 1,165.3 million. This corresponds to moderate organic sales growth of 3.6% compared to the same period of the previous year. Some markets relevant to HARTMANN are still performing below pre-pandemic levels. Adjusted EBITDA amounted to EUR 92.7…

The first quarter of 2023 saw a continuation of the sales and earnings levels of the previous two quarters as the business continued to be characterized by high additional material costs and reduced market demand. In particular, demand for disinfection products remained below pre-pandemic levels. Inflation also led to reduced purchasing power,…

HARTMANN publishes Quarterly Report 3/2022. Business developments affected by a tense economic and geopolitical situation.

Company already complies with all requirements of the EU Medical Device Regulation (MDR).